Quantcast

Latest South San Francisco, California Stories

2014-07-01 08:29:44

Former Genentech executive to lead Moderna's first venture company, focused exclusively in novel biology for oncology drug development CAMBRIDGE, Mass., July 1, 2014 /PRNewswire/ -- Moderna Therapeutics, the pioneer in developing messenger RNA (mRNA) Therapeutics(TM), a revolutionary treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stephen Kelsey, M.D., will become president of Onkaido Therapeutics, Moderna's oncology drug development...

2014-06-12 08:21:25

Rooms at San Francisco airport hotel now boast new bedding, furniture, décor to satisfy travelers' evolving desires SOUTH SAN FRANCISCO, Calif., June 12, 2014 /PRNewswire-iReach/ -- Travelers headed to the Bay Area this summer are in for an extra special touch of comfort when they stay at the Courtyard San Francisco Airport/Oyster Point Waterfront. The San Francisco airport hotel has just completed a major room renovation project that adds intuitive features and thoughtful touches...

2014-06-10 16:27:04

INCLINE VILLAGE, Nev., June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million, as compared with actual revenue of $143.6 million for the second quarter of 2013, an approximate 3 percent decrease. The forecasted revenues are driven by increased first quarter 2014 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®) and Actemra(®) for which PDL...

2014-03-26 08:28:26

VANCOUVER, British Columbia, March 26, 2014 /PRNewswire/ -- Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain. The collaboration leverages Xenon's Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive...

2014-03-11 16:26:30

INCLINE VILLAGE, Nev., March 11, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase. The forecasted growth in revenues is driven by increased fourth quarter 2013 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®), and...

2014-03-03 16:25:50

- Annual Revenues Increased 18 Percent during 2013 - INCLINE VILLAGE, Nev., March 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2013. http://photos.prnewswire.com/prnvar/20110822/SF55808LOGO Total revenues in 2013 increased 18 percent to $442.9 million from $374.5 million in 2012. For the fourth quarter of 2013, total revenues were $110.1 million, compared to $86.0 million in...

2014-02-25 08:33:25

MOUNTAIN VIEW, Calif., Feb. 25, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that Robert A. Lippe has joined the Company as Executive Vice President, Operations and Chief Operations Officer. In this newly created position, Mr. Lippe has responsibility for the Company's global operation functions, including strategic development and execution of clinical and commercial manufacturing, quality and compliance, supply chain and supply partner...

2014-02-03 08:27:04

INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. (Logo:...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related